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Introduction
Spinal administration of morphine is one of the most common clinical procedures for pain relief because of its long-lasting analgesic effects [7, 8] . However, itch/pruritus is characteristic of intrathecal morphine treatment, with reported incidence rates ranging from 30% to 100% in humans [36] . Such unique physiological functions of intrathecal morphine can also be observed in non-human primates. For example, a single antinociceptive dose of intrathecal morphine elicited profound long-lasting itch/scratching responses in monkeys [17] . Importantly, pharmacological studies using monkeys have demonstrated that opioid analgesic-induced scratching response is selectively mediated by mu opioid receptors (MOP) [18] and that kappa opioid receptor (KOP) agonists have the therapeutic potential as antipruritics under this context [20, 25] . These findings support that clinically used drugs with low or moderate intrinsic efficacy on MOP or/and KOP are effective in alleviating opioid-induced itch [9, 12, 38] . Nevertheless, identification of novel targets as spinal analgesics devoid of MOP-induced pruritic effects still remains a challenge to the drug development.
Since the identification of the nociceptin/orphanin FQ (N/OFQ) peptide as the endogenous ligand of the N/OFQ peptide (NOP) receptor [26, 33] , this novel peptide receptor system has been implicated in the modulation of pain [23, 39] . A variety of pain assays in rodents have shown the effect of intrathecally administered N/OFQ to be antinociceptive [11, 29] . Peculiarly, unlike dual actions of intrathecal N/OFQ in rodents [13, 35] , intrathecal N/OFQ over a wide dose range only produced antinociceptive effects in monkeys [21] . More interestingly, using an established itch behavioral assay in monkeys [17] , intrathecal N/OFQ produced dose-dependent antinociception without eliciting scratching responses [19, 21] . These findings indicate that NOP receptor agonists may represent a promising target as spinal analgesics.
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